Vaccinex
VCNX1.0000.00% ( 0.000 )
Overview
Vaccinex (VCNX)
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 1.000
- Volume
- 26
- Turnover
- 20
- Avg Price
- 0.769
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 1.500
- Volume Ratio
- 0.02
- Turnover Ratio
- 0.00%
- 52wk Low
- 0.310
- Float Mkt Cap
- 1.62M
- Market CapUSD
- 2.68M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -8.88
- EPSDynamic
- -8.88
- EPSStatic
- --
- BVPS
- -1.55
- P/B
- --
- Circulating Supply
- 1.62M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 2.68M
- Min lot size
- 1
- Currency
- USD
Vaccinex Analyst Rating
View moreForecast & Rating
May 18, 2021Price forecast
$1470.00146899.87%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT ·
Vaccinex says neoadjuvant melanoma pilot study links pepinemab regimens to immune remodeling, longer recurrence-free survival
- PUBT ·
Vaccinex alerts on new press release availability
- nasdaq ·
Vaccinex FY25 Net Loss Narrows
- StockTitan ·
Vaccinex Reports 2025 Annual Financial Results | VCNX Stock News
- Unusual Whales ·
KDventures' portfolio company SVF Vaccines names Raheleh Nassaji as CEO to drive SVF-001 vaccine to phase 1 trials.
- Unusual Whales ·
Vaccinex will present positive clinical results of neoadjuvant treatment with pepinemab at ASCO Annual Meeting. Enhanced immunotherapy in head and neck cancer patients.
